Bendamustine in combination with rituximab for the first-line treatment of advanced indolent non-Hodgkin's lymphoma
Following on from information provided to NICE by the company in May 2018, the appraisal of Bendamustine in combination with rituximab for the first line treatment of non-Hodgkin's lymphoma [ID434] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 434
Referral date 01 January 2011
Topic area
  • Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission: 28 January 2013
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC

Project Team

Communications manager: Alice Law
Executive Lead: TBC
Project manager:

Bijal Joshi
Technical Lead: Pilar Pinilla-Dominguez

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
31 October 2022 Discontinued. Following on from information provided to NICE by the company in May 2018, the appraisal of Bendamustine in combination with rituximab for the first line treatment of non-Hodgkin's lymphoma [ID434] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
19 May 2016 Suspended. the Department of Health has asked the Institute to conduct an appraisal of bendamustine in combination with rituximab for the first-line treatment of advanced indolent non-Hodgkin's lymphoma. The Institute has now been informed by the company that it will no longer be pursuing a licensing application for bendamustine in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any developments.
20 January 2014

Please note that following on from advice received from the manufacturer, this appraisal will be rescheduled to align with latest regulatory expectations.

Therefore the first Committee discussion will not take place on 25 February 2014.
14 May 2013

Please note that following on from advice received from the manufacturer, this appraisal will be rescheduled to align with latest regulatory expectations.

Therefore the first Committee discussion will not take place on 9 July 2013.
26 March 2012

Please note that following on from advice received from the manufacturer, this appraisal has now been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid December 2012 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late February 2013.
4 May 2011

Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early March 2012. The deadline for submissions is expected in approximately early May 2012.

For further information on our processes and methods, please see our CHTE processes and methods manual